Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial.
Tom J, Bao M, Tsai L, Qamra A, Summers D, Carrasco-Triguero M, McBride J, Rosenberger CM, Lin CJF, Stubbings W, Blyth KG, Carratalà J, François B, Benfield T, Haslem D, Bonfanti P, van der Leest CH, Rohatgi N, Wiese L, Luyt CE, Kheradmand F, Rosas IO, Cai F. Tom J, et al. Among authors: mcbride j. Crit Care Med. 2022 Mar 1;50(3):398-409. doi: 10.1097/CCM.0000000000005229. Crit Care Med. 2022. PMID: 34612846 Free PMC article. Clinical Trial.
Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of RG7667, a Combination Monoclonal Antibody, for Prevention of Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients.
Ishida JH, Patel A, Mehta AK, Gatault P, McBride JM, Burgess T, Derby MA, Snydman DR, Emu B, Feierbach B, Fouts AE, Maia M, Deng R, Rosenberger CM, Gennaro LA, Striano NS, Liao XC, Tavel JA. Ishida JH, et al. Antimicrob Agents Chemother. 2017 Jan 24;61(2):e01794-16. doi: 10.1128/AAC.01794-16. Print 2017 Feb. Antimicrob Agents Chemother. 2017. PMID: 27872061 Free PMC article. Clinical Trial.
Phase 2 Randomized Trial of the Safety and Efficacy of MHAA4549A, a Broadly Neutralizing Monoclonal Antibody, in a Human Influenza A Virus Challenge Model.
McBride JM, Lim JJ, Burgess T, Deng R, Derby MA, Maia M, Horn P, Siddiqui O, Sheinson D, Chen-Harris H, Newton EM, Fillos D, Nazzal D, Rosenberger CM, Ohlson MB, Lambkin-Williams R, Fathi H, Harris JM, Tavel JA. McBride JM, et al. Antimicrob Agents Chemother. 2017 Oct 24;61(11):e01154-17. doi: 10.1128/AAC.01154-17. Print 2017 Nov. Antimicrob Agents Chemother. 2017. PMID: 28807912 Free PMC article. Clinical Trial.
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of MHAA4549A, a Monoclonal Antibody, plus Oseltamivir in Patients Hospitalized with Severe Influenza A Virus Infection.
Lim JJ, Nilsson AC, Silverman M, Assy N, Kulkarni P, McBride JM, Deng R, Li C, Yang X, Nguyen A, Horn P, Maia M, Castro A, Peck MC, Galanter J, Chu T, Newton EM, Tavel JA. Lim JJ, et al. Among authors: mcbride jm. Antimicrob Agents Chemother. 2020 Jun 23;64(7):e00352-20. doi: 10.1128/AAC.00352-20. Print 2020 Jun 23. Antimicrob Agents Chemother. 2020. PMID: 32393496 Free PMC article. Clinical Trial.
Surfactant protein D is a biomarker of influenza-related pediatric lung injury.
Chakrabarti A, Nguyen A, Newhams MM, Ohlson MB, Yang X, Ulufatu S, Liu S, Park S, Xu M, Jiang J, Halpern WG, Anania VG, McBride JM, Rosenberger CM, Randolph AG; Pediatric Intensive Care Influenza (PICFLU) Investigators. Chakrabarti A, et al. Among authors: mcbride jm. Pediatr Pulmonol. 2022 Feb;57(2):519-528. doi: 10.1002/ppul.25776. Epub 2021 Dec 7. Pediatr Pulmonol. 2022. PMID: 34842360 Free PMC article.
Prognostic value of severe acute respiratory syndrome coronavirus-2 viral load and antibodies in patients hospitalized with COVID-19.
Bauer RN, Teterina A, Shivram H, McBride J, Rosenberger CM, Cai F, Bao M, Tsai L, Gordon O, Lee IT, Wallin JJ, Porter D, Juneja K, Camus G, Rosas IO, Wildum S. Bauer RN, et al. Among authors: mcbride j. Clin Transl Sci. 2023 Jun;16(6):1049-1062. doi: 10.1111/cts.13511. Epub 2023 Mar 29. Clin Transl Sci. 2023. PMID: 36929625 Free PMC article. Clinical Trial.
A myeloid program associated with COVID-19 severity is decreased by therapeutic blockade of IL-6 signaling.
Hackney JA, Shivram H, Vander Heiden J, Overall C, Orozco L, Gao X, Kim E, West N, Qamra A, Chang D, Chakrabarti A, Choy DF, Combes AJ, Courau T, Fragiadakis GK, Rao AA, Ray A, Tsui J, Hu K, Kuhn NF, Krummel MF, Erle DJ, Kangelaris K, Sarma A, Lyon Z, Calfee CS, Woodruff PG, Ghale R, Mick E, Byrne A, Zha BS, Langelier C, Hendrickson CM, van der Wijst MGP, Hartoularos GC, Grant T, Bueno R, Lee DS, Greenland JR, Sun Y, Perez R, Ogorodnikov A, Ward A, Ye CJ; UCSF COMET Consortium; Ramalingam T, McBride JM, Cai F, Teterina A, Bao M, Tsai L, Rosas IO, Regev A, Kapadia SB, Bauer RN, Rosenberger CM. Hackney JA, et al. Among authors: mcbride jm. iScience. 2023 Sep 1;26(10):107813. doi: 10.1016/j.isci.2023.107813. eCollection 2023 Oct 20. iScience. 2023. PMID: 37810211 Free PMC article.
1,104 results